A detailed history of Morgan Stanley transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 198,480 shares of TRVI stock, worth $845,524. This represents 0.0% of its overall portfolio holdings.

Number of Shares
198,480
Previous 88,981 123.06%
Holding current value
$845,524
Previous $265,000 149.81%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.58 - $3.51 $282,507 - $384,341
109,499 Added 123.06%
198,480 $662,000
Q2 2024

Oct 17, 2024

BUY
$2.44 - $3.36 $50,639 - $69,733
20,754 Added 30.42%
88,981 $265,000
Q2 2024

Aug 14, 2024

BUY
$2.44 - $3.36 $50,639 - $69,733
20,754 Added 30.42%
88,981 $265,000
Q1 2024

Oct 17, 2024

SELL
$1.3 - $3.7 $26,980 - $76,789
-20,754 Reduced 23.32%
68,227 $235,000
Q1 2024

Aug 16, 2024

SELL
$1.3 - $3.7 $105,008 - $298,871
-80,776 Reduced 54.21%
68,227 $235,000
Q1 2024

May 15, 2024

SELL
$1.3 - $3.7 $105,008 - $298,871
-80,776 Reduced 54.21%
68,227 $235,000
Q4 2023

Aug 16, 2024

BUY
$1.06 - $2.05 $63,623 - $123,045
60,022 Added 67.45%
149,003 $199,000
Q4 2023

Feb 13, 2024

BUY
$1.06 - $2.05 $121,146 - $234,292
114,289 Added 329.23%
149,003 $199,000
Q3 2023

Nov 15, 2023

SELL
$2.11 - $2.47 $6,492 - $7,600
-3,077 Reduced 8.14%
34,714 $75,000
Q2 2023

Aug 14, 2023

BUY
$1.8 - $3.44 $67,332 - $128,680
37,407 Added 9741.41%
37,791 $90,000
Q1 2023

May 15, 2023

SELL
$1.69 - $2.97 $92 - $163
-55 Reduced 12.53%
384 $0
Q4 2022

Feb 14, 2023

SELL
$1.61 - $2.42 $689,025 - $1.04 Million
-427,966 Reduced 99.9%
439 $0
Q3 2022

Nov 14, 2022

BUY
$1.54 - $4.28 $659,743 - $1.83 Million
428,405 New
428,405 $660,000
Q2 2022

Aug 15, 2022

SELL
$1.8 - $3.39 $1,060 - $1,996
-589 Closed
0 $0
Q1 2022

Oct 27, 2022

BUY
$0.46 - $2.48 $270 - $1,460
589 New
589 $1,000
Q1 2022

May 13, 2022

BUY
$0.46 - $2.48 $270 - $1,460
589 New
589 $1,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $248M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.